Attached files
file | filename |
---|---|
8-K - FORM 8-K - NANOSPHERE INC | c17293e8vk.htm |
EX-5.1 - EX-5.1 - NANOSPHERE INC | c17293exv5w1.htm |
EX-1.1 - EX-1.1 - NANOSPHERE INC | c17293exv1w1.htm |
Exhibit 99.1
Nanosphere, Inc. Closes Common Stock Offering
Northbrook, Ill.May 13, 2011Nanosphere, Inc. (the Company) (Nasdaq:NSPH), a leader in the
development and commercialization of advanced molecular diagnostics systems, today announced the
closing of its previously announced underwritten public offering of 15,686,000 shares of its common
stock at a public offering price of $2.20 per share, including 2,046,000 shares of common stock
issued pursuant to the underwriters exercise in full of their over-allotment option. Piper Jaffray
& Co. acted as the sole book-running manager and Roth Capital Partners, LLC acted as co-manager for
the offering.
Net proceeds from the sale of the shares after underwriting discounts and commissions and other
offering expenses are expected to be approximately $32.1 million. The Company plans to use the net
proceeds from the offering for general corporate purposes and working capital.
The offering was made pursuant to a prospectus supplement to the Companys prospectus, dated
September 15, 2009, filed as part of the Companys effective $100 million shelf registration
statement. This press release shall not constitute an offer to sell or the solicitation of an offer
to buy any securities nor will there be any sale of these securities in any state in which such
offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of any such state.
Copies of the final prospectus supplement and accompanying prospectus relating to these securities
may be obtained by contacting Piper Jaffray & Co., by mail at 800 Nicollet Mall, Suite 800,
Minneapolis, MN 55402, or by telephone at (800) 747-3924.
About Nanosphere, Inc.
Nanosphere develops, manufactures and markets an advanced molecular diagnostics platform, the
Verigene® System, for direct genomic and ultra-sensitive protein detection. This easy to
use and cost effective platform enables simple, low cost and highly sensitive genomic and protein
testing on a single platform. Nanosphere is based in Northbrook, IL.
Except for historical information, the matters discussed in this press release are forward-looking
statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to risks and
uncertainties. Actual results could differ materially from these forward-looking statements.
Factors that could cause or contribute to such differences include, but are not limited to, the
following: (i) Nanospheres ability to develop commercially viable products; (ii) Nanospheres
ability to achieve profitability; (iii) Nanospheres ability to produce and market its products;
(iv) Nanospheres ability to obtain regulatory approval of its products; (v) Nanospheres ability
to protect its intellectual property; (vi) competition and alternative technologies; and (vii)
Nanospheres ability to obtain additional financing, if and when necessary, to support its
operations. Additional risks are discussed in the Companys current filings with the Securities and Exchange Commission. Although the Company believes the expectations reflected in
such forward-looking statements are based on reasonable assumptions, it can give no assurance that
its expectations will be attained. The forward-looking statements are made as of the date of this
press release, and we undertake no obligation to publicly update or revise any forward-looking
statement, whether as a result of new information, future events or otherwise.
Contact: |
||
Investors:
|
Media: | |
Nanosphere, Inc.
|
The Torrenzano Group | |
Roger Moody, 847-400-9021
|
Ed Orgon, 212-681-1700 | |
Chief Financial Officer
|
ed@torrenzano.com | |
rmoody@nanosphere.us |